

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**SEARCH REQUEST FORM**

Scientific and Technical Information Center

Requester's Full Name: R GITOMEN Examiner #: 09630 Date: 8/21/02  
Art Unit: 16287 Phone Number 308 0732 Serial Number: 09/840/97  
Mail Box and Bldg/Room Location: 30819 Results Format Preferred (circle): PAPER DISK E-MAIL  
7A11

**If more than one search is submitted, please prioritize searches in order of need.**

\*\*\*\*\*

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: \_\_\_\_\_

Inventors (please provide full names): \_\_\_\_\_

Earliest Priority Filing Date: \_\_\_\_\_

*\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Jan Delaval  
Reference Librarian  
Biotechnology & Chemical Library  
CM1 1E07 - 703-305-4490  
jan.delaval@uspto.gov

**STAFF USE ONLY**

	Type of Search	Vendors and cost where applicable
Searcher: _____	NA Sequence (#) _____	STN _____
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>8/31/02</u>	Bibliographic <input checked="" type="checkbox"/>	Dr.Link _____
Date Completed: <u>8/31/02</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Clerical Prep Time: <u>10</u>	Patent Family _____	WWW/Internet _____
Online Time: <u>+ 30</u>	Other _____	Other (specify) _____

=> d'his .

(FILE 'HOME' ENTERED AT 13:31:49 ON 31 AUG 2002)  
DEL HIS  
SET COST OFF

FILE 'REGISTRY' ENTERED AT 13:32:56 ON 31 AUG 2002  
E .ALPHA.-KERATOSE/CN

L1 1 S E3  
L2 1 S ALPHA AND KERATOSE?  
L3 1 S L1,L2

FILE 'HCAOLD' ENTERED AT 13:34:58 ON 31 AUG 2002  
L4 0 S L3

FILE 'HCAPLUS' ENTERED AT 13:35:02 ON 31 AUG 2002

L5 9 S L3  
L6 112 S (ALPHA OR ALFA) (S)KERATOSE  
L7 114 S L5,L6  
E KERATOSE/CT  
E E3+ALL  
L8 12 S E1 (L) (ALPHA OR ALFA)  
E E2+ALL  
L9 5 S E6  
L10 11 S E4 (L) (ALPHA OR ALFA)  
L11 117 S L7-L10  
L12 81 S L11 NOT TEXTILE?/SC,SX,CW  
L13 28 S L12 NOT WOOL?  
L14 18 S L13 NOT HAIR  
L15 1 S L14 AND BLOOD  
L16 2 S L11 AND BLOOD  
L17 2 S L15,L16  
L18 1 S L17 NOT HAIR  
E WIDRA A/AU  
L19 7 S E3,E4  
L20 3 S L19 AND L11  
L21 3 S L18,L20  
L22 4 S L19 NOT L21  
L23 3 S L21 AND L5-L22  
SEL RN

FILE 'REGISTRY' ENTERED AT 13:40:58 ON 31 AUG 2002  
L24 9 S E1-E9

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 13:41:24 ON 31 AUG 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 31 Aug 2002 VOL 137 ISS 10  
FILE LAST UPDATED: 30 Aug 2002 (20020830/ED)

Jan Delaval  
Reference Librarian  
Biotechnology & Chemical Library  
CM1 1E07 - 703-308-4498  
jan.delaval@uspto.gov

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d 123 all tot

L23 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2002 ACS

AN 2002:449430 HCAPLUS

DN 137:24288

TI Use of **alpha-keratose** as a **blood** plasma expander

IN **Widra, Abe**

PA USA

SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A01N043-04

ICS C12Q001-02

CC 63-3 (Pharmaceuticals)

Section cross-reference(s): 9

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002045508	A1	20020613	WO 2001-US22727	20010718
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2000-254249P P 20001208

US 2001-840197 A 20010423

AB A plasma expander and **blood** substitute comprising a therapeutic amt. of a soln. of **.alpha.-keratose**, a sol. fraction of keratin, as an oncotic agent with nutrient growth properties suitable as a transport vehicle for the natural or synthetically formed elements of **blood**. The soln. of **.alpha.-keratose** is non-antigenic, does not require **blood** typing, is free of disease producing viruses and may be stored indefinitely at ambient temps. in the lyophilized state. For example, the **blood** loss in severely stressed beagle dogs (**blood** loss of > 300 mL) was replaced with 300 mL of 2.5% **.alpha.-keratose** colloid (wt./vol.) in a crystalloid solvent Normosol R pH 7.4 during a 5.5 min time span without serious complications, thereby demonstrating the usefulness of **.alpha.-keratose** as an oncotic agent. At the conclusion of all testing, the dog was eating and looking quite strong, showing no ill effects from the expt. This expt. indicates that the **.alpha.-keratose** soln. of the present invention provides a useful transport medium for the formed cellular elements of **blood** and maintains normal vascular osmotic pressure due to its oncotic properties. A protein, the extn./genesis of which took place at refrigerator temp. (4.degree., to prevent possible heat denaturation) is not subject to freezing under the same condition. Indeed, 2.5% **.alpha.-keratose** in salt soln. does not freeze or become noticeably more

viscous from 12.degree. down to 2.degree., thereby allowing its use in hypothermic applications of the transfusion art, such as, but not limited to, open-heart surgery and organ transplantation.

ST keratose **blood** substitute organ preservation cell culture

IT **Blood** substitutes

Electrolytes, biological

Physiological saline solutions

(.alpha.-keratose soln. as **blood** plasma expander)

IT Salts, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(.alpha.-keratose soln. as **blood** plasma expander)

IT **Blood** serum

(.alpha.-keratose soln. as **blood** plasma expander and for serum-free cell culture)

IT Animal tissue culture

(.alpha.-keratose soln. as **blood** plasma expander for growth of isolated cells)

IT Organ preservation

Preservation solutions (tissue)

(.alpha.-keratose soln. as **blood** plasma expander for maintaining isolated organ)

IT Mammalia

Shock (circulatory collapse)

(.alpha.-keratose soln. as **blood** plasma expander for treatment of mammal in shock)

IT Pathogen

Poisons, nonbiological source

(.alpha.-keratose soln. as **blood** plasma expander in removal of pathogens, poisons, and toxins from **blood**)

IT Toxins

RL: REM (Removal or disposal); PROC (Process)

(.alpha.-keratose soln. as **blood** plasma expander in removal of pathogens, poisons, and toxins from **blood**)

IT **Blood** cell

**Blood** transfusion

(.alpha.-keratose soln. as **blood** plasma expander in removal of pathogens, poisons, and toxins from **blood** and resuspending **blood** cells)

IT 50-99-7, Dextrose, biological studies 7647-14-5, Sodium chloride, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(.alpha.-keratose soln. as **blood** plasma expander)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Chunippon Seni Kogyo Kyodo Kumiai; JP 10077210 A 1998 HCAPLUS

(2) Ewald, R; Proceedings for the Society for Experimental Biology and Medicine 1964, V115(1), P130

(3) Segal; US 5698536 A 1997 HCAPLUS

(4) Taylor; US 5405742 A 1995 HCAPLUS

(5) University Of Illinois Foundation; EP 0089152 A1 1983 HCAPLUS

L23 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2002 ACS

AN 1985:427348 HCAPLUS

DN 103:27348

TI Hydrophilic biopolymeric copolyelectrolytes for biodegradable wound dressings

IN Widra, Abe

PA University of Illinois Foundation, USA

SO Eur. Pat. Appl., 33 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 IC ICM A61L015-04  
 ICS A61L027-00; C08L089-00; C08L005-08  
 CC 63-7 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 138385	A2	19850424	EP 1984-306266	19840913
	EP 138385	A3	19870114		
	EP 138385	B1	19900418		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	CA 1213521	A1	19861104	CA 1984-456295	19840611
	AT 52034	E	19900515	AT 1984-306266	19840913
	JP 60122568	A2	19850701	JP 1984-198384	19840921
	JP 06014956	B4	19940302		
PRAI	US 1983-534486		19830921		
	EP 1984-306266		19840913		

AB Hydrogel membranes as biodegradable dressings for denuded tissue wound sites such as burn wounds and ulcerations, are water-insol., water-swallowable materials comprising a water-sol. linear anionic polyelectrolyte component derived from keratin and a water-sol. linear cationic biopolymer polyelectrolyte component derived from at least 1 biopolymer consisting of a glucosaminoglycan such as chitosan and the protein collagen. In their hydrated form, the copolyelectrolytes are stress durable hydrogels which can be manipulated like a self-annealing paste or putty and thereby formed into membrane sheets. The copolyelectrolytes can be regenerated by the addn. of water from their dehydrated form to their hydrogen form, and reshaped. Thus, a chitosan collagen keratinate copolyelectrolyte was prepd. by mixing chitosan acetate 30, collagen acetate 10, and ammonium keratinate 10 mL to pptn. end-point. Upon evapn. of the supernatant, the ppt. dried to a cryst.-like sheet which upon addn. of water resulted in a hydrogel membrane. The effectiveness of a hydrogel membrane contg. gentamycin sulfate [1405-41-0] was demonstrated in a patient with multiple leg ulcers.

ST biopolymer copolyelectrolyte biodegradable wound dressing

IT Collagens, compounds

RL: BIOL (Biological study)

(acetates, complexes with ammonium keratinate and chitosan acetate, as biodegradable wound dressing)

IT Surgical dressings and goods

(biodegradable, chitosan-collagen keratinate copolyelectrolytes as)

IT Antibiotics

(chitosan-collagen keratinate copolyelectrolyte hydrogel wound dressing contg.)

IT Membrane, biological

(copolyelectrolyte hydrogels, as wound dressings)

IT Biopolymers

RL: BIOL (Biological study)

(copolyelectrolytes, as biodegradable wound dressings)

IT Polyelectrolytes

(anionic, biodegradable wound dressings)

IT Polyelectrolytes

(cationic, biodegradable wound dressings)

IT Gels

(hydro-, copolyelectrolytes, as wound dressings)

IT Surgical dressings and goods

(tubing, chitosan-collagen keratinate for)

IT Keratins

RL: BIOL (Biological study)

(..alpha.-keratoses, ammonium salts, complexes with chitosan and collagen acetates as biodegradable wound dressings)  
 IT 42617-20-9D, complexes with ammonium keratinate  
 RL: BIOL (Biological study)  
 (biodegradable wound dressings)  
 IT 127-33-3 1403-66-3 1405-41-0 35607-66-0 62893-20-3  
 RL: BIOL (Biological study)  
 (chitosan-collagen keratinate copolyelectrolyte hydrogel wound dressing contg.)

L23 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2002 ACS  
 AN 1983:581516 HCAPLUS  
 DN 99:181516  
 TI Hydrophilic bipolymeric copolyelectrolytes, and biodegradable wound dressings comprising them  
 IN Widra, Abe  
 PA University of Illinois Foundation, USA  
 SO Eur. Pat. Appl., 24 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 IC A61L015-04; C08H001-00; C08B037-08  
 CC 63-7 (Pharmaceuticals)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 89152	A1	19830921	EP 1983-301149	19830303
	EP 89152	B1	19861015		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	CA 1213520	A1	19861104	CA 1983-421701	19830216
	AT 22805	E	19861115	AT 1983-301149	19830303
	FI 8300838	A	19830918	FI 1983-838	19830314
	FI 71944	B	19861128		
	FI 71944	C	19870309		
	DK 8301219	A	19830918	DK 1983-1219	19830316
	NO 8300934	A	19830919	NO 1983-934	19830316
	ES 520658	A1	19840501	ES 1983-520658	19830316
	JP 58170721	A2	19831007	JP 1983-45261	19830317
	JP 03047867	B4	19910722		
PRAI	US 1982-358994		19820317		
	EP 1983-301149		19830303		

AB Hydrophilic biopolymer polyelectrolytes prep'd. from a water-sol. linear anionic protein polyelectrolyte component derived from keratin and a water-sol. linear cationic component from chitosans or collagen salts are useful as dressings for burn wounds. These polyelectrolyte membranes are rapidly, uniformly and strongly adherent to the underlying tissues by virtue of their shrinkdown from the fully hydrated state. In addn., they are durable to phys. stress and may be thickened and have a high degree of absorbent capacity for blood exudates. Collagen acetate was prep'd. from collagen fibers by treatment with 0.25% HOAc. .alpha.-Keratose ammonium keratinate soln. was prep'd. by treatment of human hair with water and peracetic acid for 24 h followed by removal of the acid. Washed hair was treated with 3N NH4OH and stirred for 24 h. The solubilized .alpha.-keratose ammonium keratinate was further purified and treated with collagen acetate soln. to yield a mixed soln. The soln. was evap'd. to give a ppt. and the ppt. dried to give a cryst.-like sheet. On adding water to the ppt., a self-annealed diaphanous, flexuous cohesive collagen keratinate polyelectrolyte membrane was formed. The effectiveness of the membrane in wound healing was demonstrated in rabbits.  
 ST polymer polyelectrolyte membrane; wound dressing polymer polyelectrolyte; chitosan collagen surgical dressing  
 IT Collagens, compounds

RL: PREP (Preparation)  
 (acetates, reaction products with **.alpha.-keratose**  
 ammonium keratinate, prepn. of, for wound dressings)

IT Surgical dressings and goods  
 (chitosan or collagen salt reaction products with ammonium keratinate  
 for)

IT Polyelectrolytes  
 (collagen or chitosan salt reaction products with ammonium keratinate,  
 for wound dressings)

IT Membrane, biological  
 (polyelectrolyte polymer, for wound dressings)

IT **Keratins**  
 RL: BIOL (Biological study)  
 (**.alpha.-keratoses**, ammonium salts, reaction  
 products with chitosan or collagen salts, for wound dressings)

IT 9012-76-4DP, reaction products with **.alpha.-keratose**  
 ammonium keratinate 42617-20-9DP, reaction products with **.alpha.**  
**-keratose** ammonium keratinate  
 RL: PREP (Preparation)  
 (prepn. of, for wound dressings)

=> fil wpix  
 FILE 'WPIX' ENTERED AT 13:57:06 ON 31 AUG 2002  
 COPYRIGHT (C) 2002 THOMSON DERWENT

FILE LAST UPDATED: 29 AUG 2002 <20020829/UP>  
 MOST RECENT DERWENT UPDATE 200255 <200255/DW>  
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> SLART (Simultaneous Left and Right Truncation) is now  
 available in the /ABEX field. An additional search field  
 /BIX is also provided which comprises both /BI and /ABEX <<<

>>> The BATCH option for structure searches has been  
 enabled in WPINDEX/WPIDS and WPIX <<<

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,  
 SEE <http://www.derwent.com/dwpi/updates/dwpcov/index.html> <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
 PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
 GUIDES, PLEASE VISIT:  
[http://www.derwent.com/userguides/dwpi\\_guide.html](http://www.derwent.com/userguides/dwpi_guide.html) <<<

=> d all abeq tech abex tot 146

L46 ANSWER 1 OF 2 WPIX (C) 2002 THOMSON DERWENT  
 AN 1985-100548 [17] WPIX  
 CR 1983-772432 [39]  
 DNN N1985-075468 DNC C1985-043443  
 TI Keratin-collagen-glucosamino glycan membranes - for dressing  
**wounds.**  
 DC A96 D22 P34  
 IN **WIDRA, A**  
 PA (UNII) UNIV ILLINOIS FOUND  
 CYC 14  
 PI EP 138385 A 19850424 (198517)\* EN 33p



R: AT BE CH DE FR GB IT LI NL SE

JP 60122568 A 19850701 (198532)

US 4570629 A 19860218 (198610)

CA 1213521 A 19861104 (198649)

EP 138385 B 19900418 (199016)

R: AT BE CH DE FR GB IT LI NL SE

DE 3481974 G 19900523 (199022)

JP 06014956 B2 19940302 (199412)

A61L015-16

ADT EP 138385 A EP 1984-306266 19840913; JP 60122568 A JP 1984-198384  
19840921; US 4570629 A US 1983-534486 19830921; JP 06014956 B2 JP  
1984-198384 19840921

FDT JP 06014956 B2 Based on JP 60122568

PRAI US 1982-358994 19820317; US 1983-534486 19830921

REP A3...8702; EP 89152; GB 2026516; No-SR.Pub; US 4280954

IC A61L015-04; A61L027-00; A61M005-20; C07K015-02; C08L005-08; C08L089-00

ICM A61L015-16

ICS A61L015-04; A61L015-44; A61L017-00; A61L027-00; A61M005-20;

C07K015-02; C08L005-08; C08L089-00

AB EP 138385 A UPAB: 19940510

Hydrophilic biopolymeric copolyelectrolytes used as biodegradable dressings for **wounds** are claimed which are an integral mixt. or layers of:

(a) a water-soluble linear anionic protein polyelectrolyte derived from keratin, pref. ammonium ketatinate contg. **alpha-keratose**; and (b) a water-soluble linear cationic biopolymer polyelectrolyte selected from a glucosaminoglycan (pref. chitosan) and collagen in a wt. ratio of 2:1-13:1 (pref. 0.001:1-1:1).

The dressings can opt. contain plasticisers or softeners (pref. glycerol) and an antibiotic. Membranes comprising at least 1 layer of a hydrogel formed from this compsn. are also claimed.

ADVANTAGE - The hydrogel membranes are strongly adherent to underlying tissues, elastic, permeable to O<sub>2</sub> and water vapour, absorb **wound** exudates and are a barrier to bacteria.

Dwg.0/0

FS CPI GMPI

FA AB

MC CPI: A03-C01; A07-A01; A12-V03A; D09-C

ABEQ EP 138385 B UPAB: 19930925

A hydrophilic biopolymeric copolyelectrolyte of (a) a water-soluble linear anionic protein polyelectrolyte component derived from keratin, and (b) a water-soluble linear cationic biopolymer polyelectrolyte component derived from at least one biopolymer selected from a glucosaminoglycan and collagen, the weight ratio of said anionic protein polyelectrolyte component to said cationic biopolymer polyelectrolyte component lying within the range of from 0.001:1 to 16:1 but outside the range of from 1:1 to 10:1.

ABEQ US 4570629 A UPAB: 19930925

Novel hydrophilic biopolymeric copolyelectrolyte, comprises (a) a water-soluble linear anionic keratin-derived protein poly-electrolyte component; and (b) a water-soluble linear cationic biopolymer polyelectrolyte comprising glucosaminoglycan and/or collagen.

Pref. wt. ratio (a):(b) is 0.001-7:1 such that (a) is ammonium keratinate, and (b) is chitosan or chitosan/collagen in wt. ratio 0.5-13:1. Compsn. further comprises a flexibility- and/or adhesion-enhancing amt. of non-toxic plasticiser or softener (e.g. glycerol).

USE - As biodegradable dressings for denuded tissue **wound** sites.

L46 ANSWER 2 OF 2 WPIX (C) 2002 THOMSON DERWENT

AN 1983-772432 [39] WPIX

CR 1985-100548 [17]

DNN N1983-170058 DNC C1983-092450

TI Hydrophilic bio polymeric co polyelectrolytes - of water soluble linear

anionic protein polyelectrolyte derived from keratin and water soluble linear cationic bio polymer.

DC A11 A96 P32 P34

IN **WIDRA, A**

PA (UNII) UNIV ILLINOIS FOUND

CYC 19

PI EP 89152 A 19830921 (198339)\* EN 24p

R: AT BE CH DE FR GB IT LI LU NL SE

JP 58170721 A 19831007 (198346)

NO 8300934 A 19831010 (198347)

DK 8301219 A 19831114 (198401)

FI 8300838 A 19831130 (198403)

PT 76405 A 19840315 (198416)

ES 8404392 A 19840716 (198438)

EP 89152 B 19861015 (198642) EN

R: AT BE CH DE FR GB IT LI LU NL SE

DE 3366839 G 19861120 (198648)

CA 1213520 A 19861104 (198649)

JP 03047867 B 19910722 (199133)

ADT EP 89152 A EP 1982-301149 19820303; JP 03047867 B JP 1983-45261 19830317

PRAI US 1982-358994 19820317; US 1983-534486 19830921

REP EP 38628; FR 2318189; FR 2332863; FR 2432046

IC A61F001-00; A61K015-04; A61K031-72; A61K037-12; A61L015-04; A61L027-00; A61M001-03; C08B037-08; C08H001-00; C08L089-00

AB EP 89152 A UPAB: 19940510

Hydrophilic biopolymeric copolyelectrolyte (I) of (a) a water soluble linear anionic protein polyelectrolyte component derived from keratin and (b) a water soluble linear cationic biopolymer polyelectrolyte component derived from a glucosaminoglycan and/or collagen is new.

Pref. (a) is ammonium keratinate (the keratin is esp. **alpha-keratose**); the glucosaminoglycan is chitosan, and (b) is a biopolymer carboxylate (esp. biopolymer acetate) or a mixt. of chitosan and collagen in wt. ratio 0.5-2:1. Pref. the wt. ratio of (a) to (b) is 1-10 (esp. 2-5):1.

(I) can be used in the form of hydrogel membranes, as biodegradable dressings, for burn **wounds** and other derived tissue **wound** sites. The dressing is adherent to derived tissues, elastic, durable and completely biodegradable so as to eliminate the necessity for its being stripped from the **wound** site. It is also adsorbent to **wound** exudates without losing its durability and has water vapour characteristic sufficient to keep the underlying tissues moist without creating pooling.

Dwg.0/0

FS CPI GMPI

FA AB

MC CPI: A03-A; A03-C01; A12-M02; A12-V03A

ABEQ EP 89152 B UPAB: 19930925

A hydrophilic biopolymeric copolyelectrolyte of (a) a water-soluble linear anionic protein polyelectrolyte component derived from keratin and (b) a water-soluble linear cationic biopolymer polyelectrolyte component derived from at least one biopolymer selected from a glucosaminoglycan and collagen.

=> d his

(FILE 'HOME' ENTERED AT 13:31:49 ON 31 AUG 2002)

DEL HIS

SET COST OFF

FILE 'REGISTRY' ENTERED AT 13:32:56 ON 31 AUG 2002

E .ALPHA.-KERATOSE/CN

L1 1 S E3

L2 1 S ALPHA AND KERATOSE?  
L3 1 S L1,L2

FILE 'HCAOLD' ENTERED AT 13:34:58 ON 31 AUG 2002  
L4 0 S L3

FILE 'HCAPLUS' ENTERED AT 13:35:02 ON 31 AUG 2002  
L5 9 S L3  
L6 112 S (ALPHA OR ALFA) (S)KERATOSE  
L7 114 S L5,L6  
E KERATOSE/CT  
E E3+ALL  
L8 12 S E1(L) (ALPHA OR ALFA)  
E E2+ALL  
L9 5 S E6  
L10 11 S E4(L) (ALPHA OR ALFA)  
L11 117 S L7-L10  
L12 81 S L11 NOT TEXTILE?/SC, SX, CW  
L13 28 S L12 NOT WOOL?  
L14 18 S L13 NOT HAIR  
L15 1 S L14 AND BLOOD  
L16 2 S L11 AND BLOOD  
L17 2 S L15,L16  
L18 1 S L17 NOT HAIR  
E WIDRA A/AU  
L19 7 S E3,E4  
L20 3 S L19 AND L11  
L21 3 S L18,L20  
L22 4 S L19 NOT L21  
L23 3 S L21 AND L5-L22  
SEL RN

FILE 'REGISTRY' ENTERED AT 13:40:58 ON 31 AUG 2002  
L24 9 S E1-E9

FILE 'HCAPLUS' ENTERED AT 13:41:24 ON 31 AUG 2002

FILE 'BIOSIS' ENTERED AT 13:42:10 ON 31 AUG 2002  
L25 1 S L3  
L26 21 S L6  
L27 2 S (ALPHA OR ALFA) ( )KERATOSE  
L28 21 S L25-L27  
E WIDRA A/AU  
L29 7 S E3  
L30 0 S L28 AND L29

FILE 'EMBASE' ENTERED AT 13:45:32 ON 31 AUG 2002  
L31 0 S L1  
L32 0 S L27  
E KERATOSE/CT

FILE 'MEDLINE' ENTERED AT 13:46:07 ON 31 AUG 2002  
L33 2 S L1 OR L27

FILE 'DRUGLAUNCH' ENTERED AT 13:46:28 ON 31 AUG 2002  
L34 0 S L27

FILE 'BIOBUSINESS' ENTERED AT 13:47:03 ON 31 AUG 2002  
L35 0 S L1 OR L27

FILE 'CBNB' ENTERED AT 13:47:29 ON 31 AUG 2002  
L36 0 S L27

L37 FILE 'DRUGU' ENTERED AT 13:50:20 ON 31 AUG 2002  
0 S L27

L38 FILE 'IMSDRUGCONF' ENTERED AT 13:51:11 ON 31 AUG 2002  
0 S L27

L39 FILE 'PHARMAML' ENTERED AT 13:51:52 ON 31 AUG 2002  
0 S L27

L40 FILE 'PHIC' ENTERED AT 13:52:04 ON 31 AUG 2002  
0 S L27

L41 FILE 'PROMT' ENTERED AT 13:52:31 ON 31 AUG 2002  
0 S L1 OR L27

FILE 'WPIX' ENTERED AT 13:53:00 ON 31 AUG 2002

L42 6 S L27

L43 2 S L42 AND WOUND

L44 4 S L42 NOT L43  
E R12587+ALL/DCN  
E R01636+ALL/DCN  
E R01655+ALL/DCN  
E R01372+ALL/DCN  
E 9822-B4501+ALL/DCN  
E WIDRA A/AU  
E E3

L45 2 S E3

L46 2 S L43,L45

L47 8 S (ALPHA OR ALFA) ()KERATIN

FILE 'WPIX' ENTERED AT 13:57:06 ON 31 AUG 2002

=> fil uspatall

FILE 'USPATFULL' ENTERED AT 14:01:15 ON 31 AUG 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:01:15 ON 31 AUG 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib ab hit tot 151

L51 ANSWER 1 OF 5 USPATFULL

AN 93:74190 USPATFULL

TI Production of bioadhesive precursor protein analogs by genetically engineered organisms

IN Maugh, Kathy J., Walnut, CA, United States  
Anderson, David M., Rockville, MD, United States  
Strausberg, Susan L., Silver Spring, MD, United States  
Strausberg, Robert, Silver Spring, MD, United States  
Wei, Tena, Rockville, MD, United States

PA Enzon, Inc., Piscataway, NJ, United States (U.S. corporation)

PI US 5242808 19930907

AI US 1991-644745 19910123 (7)

DCD 20080917

RLI Continuation of Ser. No. US 1987-25243, filed on 12 Mar 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-933945, filed on 24 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1984-650128, filed on 13 Sep 1984, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Schwartz, Richard A.; Assistant Examiner: Mosher, Mary E.

LREP Sterne, Kessler, Goldstein & Fox

CLMN Number of Claims: 37  
ECL Exemplary Claim: 1  
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)  
LN.CNT 1993

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant production of bioadhesive precursor protein analogs is disclosed. The bioadhesive precursor protein analogs can be hydroxylated and used as an adhesive in wet environments.

DETD In a similar manner, other types of insoluble or crystalline protein sheets can be used as reinforcement for adhesive protein. For example, silk cloth, or sheets formed from solubilized and reprecipitated **alpha-keratose** from wool keratin fibers (J. De Bersagbes, Curr. Probl. Dermatol., 6:34-86 (1976)), or polymerized fibrin clot formed from purified fibrinogen, thrombin and Factor VIII (Redl, H. and G. Schlag, Facial Plastic Surgery, 2:315-321 (1985)) are used. For medical applications, the use of sheets of fibrin may have the additional benefit of helping to promote wound healing (Redl and Schlag, supra).

L51 ANSWER 2 OF 5 USPATFULL

AN 93:29134 USPATFULL

TI Bioadhesive precursor protein expression vectors

IN Maugh, Kathy J., Walnut, CA, United States  
Anderson, David M., Rockville, MD, United States  
Strausberg, Robert, Silver Spring, MD, United States  
Strausberg, Susan L., Silver Spring, MD, United States  
McCandliss, Russ, Gaithersburg, MD, United States  
Wei, Tena, Rockville, MD, United States  
Filpula, David, Gaithersburg, MD, United States

PA Enzon Labs, Inc., Gaithersburg, MD, United States (U.S. corporation)

PI US 5202256 19930413

AI US 1991-745695 19910816 (7)

RLI Division of Ser. No. US 1990-530449, filed on 30 May 1990, now patented, Pat. No. US 5049504 which is a continuation of Ser. No. US 1987-82456, filed on 7 Aug 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-933945, filed on 24 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1984-650128, filed on 13 Sep 1984, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Schwartz, Richard A.; Assistant Examiner: Mosher, Mary E.

LREP Sterne, Kessler, Goldstein & Fox

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 12 Drawing Figure(s); 14 Drawing Page(s)

LN.CNT 2797

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Vectors are provided that are capable of expressing, in microbial transformants, a protein having the native amino acid sequence of a bioadhesive precursor protein of a marine animal selected from the group consisting of mussels, barnacles, and oysters. The bioadhesive precursor protein can be expressed in transformants, recovered and converted to a bioadhesive protein by hydroxylation.

DETD In a similar manner, other types of insoluble or crystalline protein sheets can be used as reinforcement for adhesive protein. For example, silk cloth, or sheets formed from solubilized and reprecipitated **alpha-keratose** from wool keratin fibers (J. De Bersagbes, Curr. Probl. Dermatol., 6:34-86 (1976)), or polymerized fibrin clot formed from purified fibrinogen, thrombin and Factor VIII (Redl, H. and G. Schlag, Facial Plastic Surgery, 2:315-321 (1985)) are used. For medical applications, the use of sheets of fibrin may have the additional benefit of helping to promote wound healing (Redl and Schlag,

supra).

L51 ANSWER 3 OF 5 USPATFULL

AN 93:29116 USPATFULL

TI Method of producing bioadhesive protein

IN Maugh, Kathy J., Walnut, CA, United States

Anderson, David M., Rockville, MD, United States

Strausberg, Robert, Silver Springs, MD, United States

Strausberg, Susan L., Silver Springs, MD, United States

PA Enzon Labs Inc., Gaithersburg, MD, United States (U.S. corporation)

PI US 5202236 19930413

AI US 1990-528762 19900525 (7)

RLI Division of Ser. No. US 1987-82456, filed on 7 Aug 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-933945, filed on 24 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1984-650128, filed on 13 Sep 1984, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Schwartz, Richard A.; Assistant Examiner: Mosher, Mary E.

LREP Sterne, Kessler, Goldstein & Fox

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 13 Drawing Figure(s); 14 Drawing Page(s)

LN.CNT 1839

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Vectors are provided that are capable of expressing, in microbial transformants, a protein having the native amino acid sequence of a bioadhesive precursor protein of a marine animal selected from the group consisting of mussels, barnacles, and oysters. The bioadhesive precursor protein can be expressed in transformants, recovered and converted to a bioadhesive protein by hydroxylation.

DETD In a similar manner, other types of insoluble or crystalline protein sheets can be used as reinforcement for adhesive protein. For example, silk cloth, or sheets formed from solubilized and reprecipitated **alpha-keratose** from wool keratin fibers (J. De Bersagbes, Curr. Probl. Dermatol., 6:34-86 (1976)), or polymerized fibrin clot formed from purified fibrinogen, thrombin and Factor VIII (Redl, H. and G. Schlag, Facial Plastic Surgery, 2:315-321 (1985)) are used. For medical applications, the use of sheets of fibrin may have the additional benefit of helping to promote wound healing (Redl and Schlag, supra).

L51 ANSWER 4 OF 5 USPATFULL

AN 91:75651 USPATFULL

TI Bioadhesive coding sequences

IN Maugh, Kathy J., Walnut, CA, United States

Anderson, David M., Rockville, MD, United States

Strausberg, Robert, Silver Spring, MD, United States

Strausberg, Susan L., Silver Spring, MD, United States

McCandliss, Russ, Gaithersburg, MD, United States

Wei, Tena, Rockville, MD, United States

Filpula, David, Gaithersburg, MD, United States

PA Genex Corporation, Gaithersburg, MD, United States (U.S. corporation)

PI US 5049504 19910917

AI US 1990-530449 19900530 (7)

RLI Continuation of Ser. No. US 1987-82456, filed on 7 Aug 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-933945, filed on 24 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1984-650128, filed on 13 Sep 1984, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Schwartz, Richard A.; Assistant Examiner: Mosher, Mary

E.  
LREP Sterne, Kessler, Goldstein & Fox  
CLMN Number of Claims: 30  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 14 Drawing Page(s)  
LN.CNT 1865

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Vectors are provided that are capable of expressing, in microbial transformants, a protein having the native amino acid sequence of a bioadhesive precursor protein of a marine animal selected from the group consisting of mussels, barnacles, and oysters. The bioadhesive precursor protein can be expressed in transformants, recovered and converted to a bioadhesive protein by hydroxylation.

DETD In a similar manner, other types of insoluble or crystalline protein sheets can be used as reinforcement for adhesive protein. For example, silk cloth, or sheets formed from solubilized and reprecipitated **alpha-keratose** from wool keratin fibers (J. De Bersagbes, Curr. Probl. Dermatol., 6:34-86 (1976)), or polymerized fibrin clot formed from purified fibrinogen, thrombin and Factor VIII (Redl, H. and G. Schlag, Facial Plastic Surgery, 2:315-321 (1985)) are used. For medical applications, the use of sheets of fibrin may have the additional benefit of helping to promote wound healing (Redl and Schlag, supra).

L51 ANSWER 5 OF 5 USPATFULL

AN 86:8792 USPATFULL

TI Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same

IN Widra, Abe, River Forest, IL, United States

PA University of Illinois Foundation, Urbana, IL, United States (U.S. corporation)

PI US 4570629 19860218

AI US 1983-534486 19830921 (6)

RLI Continuation-in-part of Ser. No. US 1982-358994, filed on 17 Mar 1982, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Rosenbaum, C. Fred; Assistant Examiner: Vinyard, Sherri E.

LREP Shimei, Barbara A.

CLMN Number of Claims: 39

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 919

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hydrophilic biopolymeric copolyelectrolytes comprising (a) a water-soluble linear anionic protein polyelectrolyte component derived from keratin and (b) a water-soluble linear cationic biopolymer polyelectrolyte component derived from at least one biopolymer selected from the group consisting of collagen and a glucosaminoglycan. Hydrogel membranes formed from the copolyelectrolytes are useful as biodegradable dressings for denuded tissue wound sites.

SUMM The hydrophilic biopolymeric copolyelectrolytes of the present invention are water-insoluble, water-swellaable materials comprising a water-soluble linear anionic protein polyelectrolyte component derived from keratin and a water-soluble linear cationic biopolymer polyelectrolyte component derived from at least one biopolymer selected from the group consisting of a glucosaminoglycan, such as chitosan, and the protein, collagen. Keratin is a protein obtained from sources such as skin, fur, hair, wool, horn, nails, claws, beaks, and scales. It may be readily isolated from its source material and separated into its **alpha-keratose** and gamma-keratose fractions by procedures well known in the art, such as, for example, as described by

Widra, Mycopathologia et Mycologia Applicata, Volume 30, pages 141-144 (1966) and Rhodes, et al., Mycopathologia et Mycologia Applicata, Volume 33, pages 345-348 (1967), incorporated herein by reference. Chitosan is the deacylated form of chitin, which is a glucosaminoglycan obtained as a major constituent of the shells of shrimp, crabs, and lobsters, the cell walls of filamentous fungi, and the exoskeletons of insects. Chitosan is commercially available in the form of fibers, for example, from Sigma-Aldrich Corporation, St. Louis, Mo. Collagen is a fibrous protein which comprises the major portion of the white fiber in connective tissues of the animal body, particularly in the skin, bones and tendons. It is commercially available in the form of soluble fibers, for example, from Sigma-Aldrich Corporation, St. Louis, Mo.

SUMM The water-soluble derivatives of keratin employed in the anionic polyelectrolyte component of the copolyelectrolytes of the present invention are linear polyelectrolytes in which the keratin moiety is in anionic form. A particularly suitable anionic keratin polyelectrolyte is ammonium keratinate, obtained as the total ammonium hydroxide-soluble fraction of peracetic acid-oxidized human hair, or the **alpha-keratose** component of this fraction, by the procedures described in the aforementioned Rhodes, et al., article. Due to evidence indicating a higher degree of nonantigenicity, the **alpha-keratose** form of ammonium keratinate is preferred.

DETD **Alpha-keratose** ammonium keratinate solution was prepared as follows. Twelve grams of clean, dry, blond human hair, previously degreased and washed, were placed in a 1 liter Erlynmeyer flask containing 320 ml of water. 80 ml of concentrated peracetic acid was added, and the flask stoppered. The contents of the flask were swirled and then placed in a refrigerator for 24 hours with occasional swirling. The bleached, easily stretched and torn ("retted") hair was then freed of the peracetic acid by decantation and thorough washing with separate water rinses. The washed retted hair was then covered with 800 ml of 3N ammonium hydroxide, and stirred in the cold for 24 hours to solubilize hair keratins. The total soluble protein (TP) fraction was then cleared of solids by centrifugation, and discarding undissolved protein and non-protein residual debris. The TP fraction was further clarified through Whatman No. 1 paper, dialyzed against water until the dialyzate wash gave only a faint positive for ammonia with Nessler's reagent, and then Seitz microfiltered. **Alpha-keratose** was precipitated from the TP fraction by incremental addition of 0.1 N hydrochloric acid while stirring. The precipitate was collected by centrifugation, and the supernatant gamma-keratose, antigenic for rabbits, was discarded. The **alpha-keratose** precipitate was washed in water, re-centrifuged, and then solubilized in 0.1N ammonium hydroxide. A second cycle of precipitation, washing, and solubilization was run on the **alpha-keratose** before final dialysis against water, concentration of the protein microfiltration, and storage in a sterile container. The resulting solution contained approximately 7.5 mg of **alpha-keratose** ammonium keratinate per ml.

DETD The collagen acetate and **alpha-keratose** ammonium keratinate stock solutions prepared in Example 1, were employed in the preparation of a collagen keratinate copolyelectrolyte. 10 ml of the collagen acetate solution (containing 20 mg of collagen acetate) and 10 ml of the ammonium keratinate solution (containing 75 mg of **alpha-keratose** ammonium keratinate) were mixed together in a plastic Petri dish to precipitation end-point. Upon evaporation of the supernatant, the precipitate dried down into a dry crystalline-like sheet. Upon adding water to the dried down precipitate, a self-annealed flexuous, diaphanous, cohesive collagen keratinate copolyelectrolyte hydrogel membrane was formed, which was teased and floated from the bottom of the dish.



- DETD The chitosan acetate and **alpha-keratose** ammonium keratinate stock solutions prepared in Example 1, were employed in the preparation of a chitosan keratinate copolyelectrolyte. Fifty mg of chitosan acetate solution (containing 250 ml of chitosan acetate) and 15 ml of the ammonium keratinate solution (containing 112.5 mg of **alpha-keratose** ammonium keratinate), were mixed together in a plastic Petri dish to precipitation end-point to produce an opaque whitish, sticky, flocculent precipitate. Upon evaporation of the supernatant, the precipitate dried down to form a hard brittle translucent sheet, which was pried or cracked from the bottom of the dish. Upon adding water to the dried material, a self-annealed, tough, stretchable, cuttable, cohesive chitosan keratinate copolyelectrolyte hydrogel membrane was formed.
- DETD All three of the stock solutions prepared in Example 1 were employed in the preparation of a chitosan-collagen keratinate copolyelectrolyte. 30 ml of the chitosan acetate solution (containing 150 mg of chitosan acetate), 10 ml of the collagen acetate solution (containing 20 mg of collagen acetate), and 10 ml of the ammonium keratinate solution (containing 75 mg of **alpha-keratose** ammonium keratinate), were mixed together in a plastic Petri dish to precipitation end-point. Upon evaporation of the supernatant, the precipitate dried down to a crystalline-like sheet. Upon adding water to the dried down precipitate, a self-annealed, flexible, cohesive chitosan-collagen keratinate copolyelectrolyte hydrogel membrane was formed, which was teased and floated from the bottom of the dish.
- DETD When the chitosan acetate sheeting was sprayed on both sides with a total of 10 ml (75 mg) of the **alpha-keratose** ammonium keratinate stock solution prepared in Example 1, the solid sheeting swelled to form a self-annealed, flexible, cohesive chitosan keratinate copolyelectrolyte hydrogel membrane.
- DETD The 9".times.12" dried chitosan acetate sheeting was sprayed on both sides with a total of about 10 ml of a 5 mg/ml **alpha-keratose** ammonium keratinate solution prepared in a manner analogous to Example 1, to form a chitosan keratinate copolyelectrolyte hydrogel membrane containing the representative antibiotic gentamycin sulfate.
- DETD Seventy ml of this chitosan acetate solution was poured into a standard plastic Petri dish (3.5" diameter) and 300 mg demeclocycline powder (Declomycin, Lederle Laboratories Div. American Cyanamid Corp., Wayne, NJ) was added with stirring. The mixture was allowed to dry down to a membrane which was then lifted out and sprayed on both sides with a total of 3 ml of a 5 mg/ml **alpha-keratose** ammonium keratinate solution prepared in a manner analogous to that of Example 1, to form a chitosan keratinate copolyelectrolyte hydrogel membrane containing the representative antibiotic demeclocycline.
- DETD Fifty eight ml of this chitosan acetate solution was poured into a standard plastic Petri dish and 1 ml glycerol and 320 mg cefoxitin powder (Mafoxin, Merck Sharp & Dohme, Rahway, NJ), were added with stirring. To this mixture was added 10 ml of a 5 mg/ml **alpha-keratose** ammonium keratinate solution prepared in a manner analogous to that of Example 1 and containing 125 mg of dissolved tetracycline (Sumycin, Squibb & Sons, Inc., Princeton, NJ). The combined mixture was allowed to dry down to a yellow-brown chitosan keratinate copolyelectrolyte hydrogel membrane containing the representative antibiotics cefoxitin and tetracycline.
- DETD The 9".times.12" dried chitosan acetate sheeting was sprayed on both sides with a total of 10 ml of a 5 mg/ml **alpha-keratose** ammonium keratinate solution prepared in a manner analogous to Example 1 and containing 191 mg dissolved carbenicillin powder (Geocillin, Roerig Div. Pfizer Pharmaceuticals, New York, NY), to form a chitosan keratinate copolyelectrolyte hydrogel membrane containing the representative antibiotics gentamycin sulfate and carbenicillin.

- DETD The ears of a ketamine-anaesthetized 10 pound male New Zealand white rabbit were shorn of hair and prepared for surgery. From the dorsal surface of one ear, a full thickness circle of skin 2.5 cm in diameter was removed, and the wound sponged dry. Sterile **alpha-keratose** ammonium keratinate solution prepared according to Example 1 was dropped into the wound area and on the surrounding shaven skin. A circular swatch of thin chitosan acetate sheeting (2.4 mg chitosan/cm.sup.2) was fitted over the wound area and surrounding skin, resulting in the formation of a chitosan keratinate copolyelectrolyte hydrogel membrane wound dressing, which became tightly bound to all surfaces in a few minutes of drying time. The area was dressed with sterile petrolatum gauze, bandaged and taped. A control ear was also prepared, wherein the wound was dressed only with sterile petrolatum gauze, bandaged and taped.
- DETD A 10 pound female rabbit was prepared for surgery and a 3.5 cm diameter full thickness of skin was removed from the left flank. The site was then sprayed with sterile **alpha-keratose** ammonium keratinate solution prepared according to Example 1, and covered with a medium weight chitosan acetate sheet (3.6 mg chitosan/cm.sup.2), dressed with petrolatum gauze, bandaged, and taped.
- DETD A 10 pound female rabbit was prepared for surgery, and a full thickness of skin removed from a rectangular area 2.5.times.3.5 cm.sup.2. After spraying the wound area with sterile **alpha-keratose** ammonium keratinate solution prepared according to Example 1, a double layer of chitosan acetate sheeting (two sheets annealed with **alpha-keratose** ammonium keratinate solution and containing a total of 6.4 mg chitosan/cm.sup.2) was applied to the wound and surrounding skin. The area was then dressed with sterile petrolatum gauze, bandaged, and taped.
- DETD A rabbit was prepared for surgery and a full thickness of skin removed from an approximately square area 4 inches.times.4 inches. After spraying the area with sterile **alpha-keratose** ammonium keratinate solution prepared according to Example 1, a double-layered chitosan acetate sheeting similar to that employed in Example 12 was applied to the wound and surrounding skin. The area was then dressed with sterile petrolatum gauze, bandaged, and taped. A control wound of the same approximate size was also prepared, and was dressed only with sterile petrolatum gauze, bandaged, and taped. The wound sites were periodically examined for wound closure. During the first three weeks P.O., wound closure proceeded in the copolyelectrolyte hydrogel membrane-covered wound at a 50% faster rate than in the control wound.
- DETD A goat was prepared for surgery, and full thicknesses of skin were removed from a rectangular area 8 inches.times.9 inches on one flank and from a rectangular area 7 inches.times.8 inches on the other flank. The smaller size wound was used as the control, and was dressed only with sterile petrolatum gauze, bandaged, and taped. The larger size wound was sprayed with sterile **alpha-keratose** ammonium keratinate solution prepared according to Example 1, overlaid with a double-layered chitosan acetate sheeting similar to that employed in Example 12, and then dressed with sterile petrolatum gauze, bandaged, and taped. The two wounds were examined periodically for wound healing and closure. After four days P.O., the copolyelectrolyte hydrogel membrane-covered wound was completely covered with fibroblasts, whereas the control wound showed no signs of healing. After 14 days P.O., the copolyelectrolyte hydrogel membrane-covered wound had closed 2 inches, while the control wound had closed less than 1 inch. After 66 days P.O., the hydrogel membrane-covered wound had been reduced to 1 inch .times.3 inches; whereas after 78 days P.O., the control wound had only closed to 2 inches.times.4 inches.
- DETD Only the upper shallow pre-tibial lesion, most resembling the experimental surgical wounds produced in rabbits, was treated at first. The lesion was saturated with a sterile 5 mg/ml solution of

**alpha-keratose** ammonium keratinate prepared in a manner analogous to that of Example 1; thereafter a chitosan sheet [prepared as in the second paragraph of Example 5, but using 2 ml of glycerol] was laid down on the saturated wound surface. This was dressed with a Telfa pad [Kendall Hospital Products Div., Chicago, IL] and gauze. The chitosan sheet absorbed liquid keratinate to form a membrane which adhered to the wound. After 8 days, it was discovered that the wound was infected; the membrane was removed, the wound cleaned, and a chitosan keratinate copolyelectrolyte hydrogel membrane containing gentamycin sulfate prepared according to Example 6 was laid on the ulcer. Obvious success in treatment of the upper shallow ulcer led to gentamycin sulfate chitosan keratinate hydrogel membrane application to the other ulcers with comparable results. Treatment of the deep finger-like ulcer and the large cratered pre-tibial ulcer containing exposed tendon and a small area of exposed bone was then begun. The ulcers were saturated with a sterile 5 mg/ml **alpha-keratose** solution as above, then overlaid with a UV-sterilized glycerinated chitosan keratinate copolyelectrolyte hydrogel membrane containing gentamycin, prepared according to Example 6. The patient noted absence of tenseness and pain within minutes after the membrane was in place. From this day onward, pre-spraying of lesions with **alpha-keratose** was discontinued. Instead, the dried-down 9".times.12" chitosan acetate sheet was simply peeled from its container form, suspended in air by a set of clips, and sprayed on both sides with a total of 10 ml **alpha-keratose** (5-7.5 mg/ml) solution prepared according to Example 1, allowed to dry in air, then UV-sterilized under polyethylene (Saran Wrap) sheeting. After about 7 weeks a five-day-old membrane forming a firm carapace on the large lesion had split and lifted off of the healing site which was covered with collagenous fibrotic material. Exudate and drainage into the gauze overwrap was minimal. The patient was ambulatory, free of pain, and discharged from the hospital two weeks later. Follow-up treatment was on an out-patient basis at progressively longer intervals, where soft degraded or hardened non-adherent membrane was simply washed or cut away, the reduced lesion was washed in 3% peroxide, and a new gentamycin sulfate chitosan keratinate copolyelectrolyte hydrogel membrane prepared as above was applied and dressed as usual. Membrane degradation over the collagen-filled granulation base continued for two more months. "Pearling" at the edge of the lesion indicated new epithelial growth. Continued reduction of the lesion by epithelial ingrowth was apparent through the next 6 months to an uneventful recovery with complete reepithelialization.

DETD The patient was given a single course of amikacin/prostaphcillin therapy by intravenous drip. No surgical intervention took place. Simultaneously, therapy using 3% peroxide washes followed by application of chitosan keratinate/gentamycin copolyelectrolyte hydrogel membranes prepared according to Example 6 and the usual Telfa and gauze overwraps was initiated. Exudate-wet outer gauze wrapping was changed 2 or 3 times daily. Telfa pads and the chitosan keratinate/gentamycin copolyelectrolyte hydrogel membranes were replaced every 4 or 5 days following a peroxide wash with gauze pad swabbing to remove detritus. Only non-adherent membrane was removed or cut away. The patient was moved to a nursing facility within two weeks where glucosaminoglycan keratinate gentamycin copolyelectrolyte hydrogel membrane therapy was continued. The patient noted absence of pain with the membrane in place. Within 3 weeks the advent of fresh granulation tissue and sealing of the wound edges was apparent. However, continuing destruction of the devitalized tendon was apparent too. The tendon was soft and freely movable while the attending physician expressed pus for bacteriological studies. It was subsequently lifted and painlessly cut out. The *Pseudomonas* organism proved to be very sensitive to carbenicillin, and so two weeks after surgery the tendon-free lesion was cleaned with peroxide and swabbing, then covered with a gentamycin/carbenicillin-

containing chitosan keratinate copolyelectrolyte hydrogel membrane prepared according to Example 9. Carbenicillin-containing solutions polymerize directly and non-uniformly with the glycan solution. Membranes containing carbenicillin must therefore be formulated by spraying the chitosan acetate sheet (in this instance containing gentamycin sulfate) with **alpha-keratose** solution containing dissolved carbenicillin powder.

DETD With a second Pasteur pipette, the chitosan acetate-coated lumen of the tube was wetted with a solution of 5 mg/ml **alpha-keratose** solution prepared in a manner analogous to Example 1; the tubing was then allowed to dry again.

DETD In order to reduce thrombogenicity in the prosthesis, heparin sodium may be dissolved in the **alpha-keratose** solution used to wet down and bind the chitosan acetate component to the tube. (Heparin polymerizes directly with the chitosan acetate solution and therefore makes uniform dispersion in chitosan acetate solutions difficult).

CLM What is claimed is:

5. The copolyelectrolyte of claim 4, wherein the keratin moiety of said ammonium keratinate is **alpha-keratose**.

=> d his

(FILE 'HOME' ENTERED AT 13:31:49 ON 31 AUG 2002)

DEL HIS  
SET COST OFF

FILE 'REGISTRY' ENTERED AT 13:32:56 ON 31 AUG 2002

E .ALPHA.-KERATOSE/CN

L1 1 S E3  
L2 1 S ALPHA AND KERATOSE?  
L3 1 S L1,L2

FILE 'HCAOLD' ENTERED AT 13:34:58 ON 31 AUG 2002

L4 0 S L3

FILE 'HCAPLUS' ENTERED AT 13:35:02 ON 31 AUG 2002

L5 9 S L3  
L6 112 S (ALPHA OR ALFA) (S)KERATOSE  
L7 114 S L5,L6  
E KERATOSE/CT  
E E3+ALL  
L8 12 S E1(L) (ALPHA OR ALFA)  
E E2+ALL  
L9 5 S E6  
L10 11 S E4(L) (ALPHA OR ALFA)  
L11 117 S L7-L10  
L12 81 S L11 NOT TEXTILE?/SC, SX, CW  
L13 28 S L12 NOT WOOL?  
L14 18 S L13 NOT HAIR  
L15 1 S L14 AND BLOOD  
L16 2 S L11 AND BLOOD  
L17 2 S L15,L16  
L18 1 S L17 NOT HAIR  
E WIDRA A/AU  
L19 7 S E3,E4  
L20 3 S L19 AND L11  
L21 3 S L18,L20  
L22 4 S L19 NOT L21  
L23 3 S L21 AND L5-L22  
SEL RN

L24 FILE 'REGISTRY' ENTERED AT 13:40:58 ON 31 AUG 2002  
9 S E1-E9

FILE 'HCAPLUS' ENTERED AT 13:41:24 ON 31 AUG 2002

L25 FILE 'BIOSIS' ENTERED AT 13:42:10 ON 31 AUG 2002  
1 S L3  
L26 21 S L6  
L27 2 S (ALPHA OR ALFA) () KERATOSE  
L28 21 S L25-L27  
E WIDRA A/AU  
L29 7 S E3  
L30 0 S L28 AND L29

FILE 'EMBASE' ENTERED AT 13:45:32 ON 31 AUG 2002  
L31 0 S L1  
L32 0 S L27  
E KERATOSE/CT

L33 FILE 'MEDLINE' ENTERED AT 13:46:07 ON 31 AUG 2002  
2 S L1 OR L27

L34 FILE 'DRUGLAUNCH' ENTERED AT 13:46:28 ON 31 AUG 2002  
0 S L27

L35 FILE 'BIOBUSINESS' ENTERED AT 13:47:03 ON 31 AUG 2002  
0 S L1 OR L27

L36 FILE 'CBNB' ENTERED AT 13:47:29 ON 31 AUG 2002  
0 S L27

L37 FILE 'DRUGU' ENTERED AT 13:50:20 ON 31 AUG 2002  
0 S L27

L38 FILE 'IMSDRUGCONF' ENTERED AT 13:51:11 ON 31 AUG 2002  
0 S L27

L39 FILE 'PHARMAML' ENTERED AT 13:51:52 ON 31 AUG 2002  
0 S L27

L40 FILE 'PHIC' ENTERED AT 13:52:04 ON 31 AUG 2002  
0 S L27

L41 FILE 'PROMT' ENTERED AT 13:52:31 ON 31 AUG 2002  
0 S L1 OR L27

L42 FILE 'WPIX' ENTERED AT 13:53:00 ON 31 AUG 2002  
6 S L27  
L43 2 S L42 AND WOUND  
L44 4 S L42 NOT L43  
E R12587+ALL/DCN  
E R01636+ALL/DCN  
E R01655+ALL/DCN  
E R01372+ALL/DCN  
E 9822-B4501+ALL/DCN  
E WIDRA A/AU  
E E3  
L45 2 S E3  
L46 2 S L43, L45  
L47 8 S (ALPHA OR ALFA) () KERATIN

FILE 'WPIX' ENTERED AT 13:57:06 ON 31 AUG 2002

L48 FILE 'JICST-EPLUS, JAPIO' ENTERED AT 13:59:09 ON 31 AUG 2002  
2 S L27

L49 FILE 'USPATFULL, USPAT2' ENTERED AT 13:59:55 ON 31 AUG 2002  
0 S L1  
L50 18 S L27  
L51 5 S L50 NOT (HAIR OR SHAMPOO)/TI

FILE 'USPATFULL, USPAT2' ENTERED AT 14:01:15 ON 31 AUG 2002